Is 17-Hydroxy-(17-beta)-androst-4-en-3-one Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use 17-Hydroxy-(17-beta)-androst-4-en-3-one? Is 17-Hydroxy-(17-beta)-androst-4-en-3-one safe for nursing mother and child? Does 17-Hydroxy-(17-beta)-androst-4-en-3-one extracts into breast milk? Does 17-Hydroxy-(17-beta)-androst-4-en-3-one has any long term or short term side effects on infants? Can 17-Hydroxy-(17-beta)-androst-4-en-3-one influence milk supply or can 17-Hydroxy-(17-beta)-androst-4-en-3-one decrease milk supply in lactating mothers?
17-Hydroxy-(17-beta)-androst-4-en-3-one lactation summary
- DrLact safety Score for 17-Hydroxy-(17-beta)-androst-4-en-3-one is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of 17-Hydroxy-(17-beta)-androst-4-en-3-one may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that 17-Hydroxy-(17-beta)-androst-4-en-3-one may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of 17-Hydroxy-(17-beta)-androst-4-en-3-one low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using 17-Hydroxy-(17-beta)-androst-4-en-3-one We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About 17-Hydroxy-(17-beta)-androst-4-en-3-one usage in lactation
17-Hydroxy-(17-beta)-androst-4-en-3-one hormone reduces Prolactin serum levels and may likely inhibit milk production mainly soon after delivery. No significant increase of 17-Hydroxy-(17-beta)-androst-4-en-3-one serum levels neither in the mother´s milk nor in the infant’s serum have been found after administration to the mother. No adverse side effects have been noticed in the infant.
Answer by DrLact: About 17-Hydroxy-(17-beta)-androst-4-en-3-one usage in lactation
Limited data indicate that a low-dose (100 mg) subcutaneous 17-Hydroxy-(17-beta)-androst-4-en-3-one pellet given to a nursing mother appears not to increase milk 17-Hydroxy-(17-beta)-androst-4-en-3-one levels markedly. 17-Hydroxy-(17-beta)-androst-4-en-3-one has low oral bioavailability because of extensive first-pass metabolism, so it is unlikely to affect the breastfed infant. One breastfed infant seemed not to be adversely affected by low-dose maternal 17-Hydroxy-(17-beta)-androst-4-en-3-one therapy.
17-Hydroxy-(17-beta)-androst-4-en-3-one Side Effects in Breastfeeding
An infant (age not stated) was breastfed (extent not stated) after implantation of 100 mg of 17-Hydroxy-(17-beta)-androst-4-en-3-one subcutaneously. No adverse effects were noted in the infant over a 5-month period.[1]
17-Hydroxy-(17-beta)-androst-4-en-3-one Possible Effects in Breastfeeding
Supraphysiologic serum levels of 17-Hydroxy-(17-beta)-androst-4-en-3-one, either from a tumor[2][3] or from exogenously administered 17-Hydroxy-(17-beta)-androst-4-en-3-one,[4] reduces milk production in postpartum women. 17-Hydroxy-(17-beta)-androst-4-en-3-one alone reduces serum prolactin;[4] however, when given in combination with estrogen and progestin, serum prolactin levels are not markedly reduced.[5] 17-Hydroxy-(17-beta)-androst-4-en-3-one was previously used therapeutically to suppress lactation, usually in combination with an estrogen.[4][5][6][7][8][9][10]
Alternate Drugs
Testosterone(Low Risk)
Progesterone(Safe)
Estradiol(Low Risk)
Estradiol Valerate(Low Risk)
Testosterone(Low Risk)